Home » Posts tagged 'results'
Tag Archives: results
#ORPH Open Orphan – PLC Notice of results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for the six months ended 30 June 2022 on 8 September 2022.
Investor presentation
Yamin ‘Mo’ Khan, Chief Executive Officer, and Leo Toole, Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on 8 September 2022 at 18:00 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Open Orphan here. Investors who already follow Open Orphan on the Investor Meet Company platform will automatically be invited.
For further information please contact:
Open Orphan plc |
+353 (0) 1 644 0007 |
||
Yamin Khan, Chief Executive Officer |
|||
Liberum Capital (Nominated Adviser and Joint Broker) |
+44 (0) 20 3100 2000 |
||
Ben Cryer/ Edward Mansfield/ Phil Walker/ Will King |
|||
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
Geoff Nash / James Thompson / Richard Chambers |
|||
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
Anthony Farrell |
|||
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Phillip Marriage / |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com +44 (0) 7796 794 663 / +44 (0) 7867 984 082 / |
||
Open Orphan #ORPH – Final results Reveal Record revenues and EBITDA-profitability accompanied by significant operational progress
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited final results for the 12 months ended 31 December 2021.
Financial highlights
· Record revenues of £39.0m (2020: £22.2m) achieved representing 76% growth
· £9m improvement in EBITDA generating £2.9m (2020: £(6.1)m)
· Cash and cash equivalents as at 31 December 2021 of £15.7m (2020: £19.2m)
· Significant EPS improvement in 2021 to (0.01)p per share (2020: (1.80)p)
· Order book growth of 11% to £46m future contracted revenue as at 31 December 2021 (2020: £41.6m)
Operational highlights
· Delivered a strong and growing pipeline of new challenge study contract wins
o Served four of the top 10 global biopharma companies in 2021 among a growing client base of over 60 clients
· Substantially expanded the Group’s offering into the respiratory market signing an asthma study with a top three global pharma company
· Completed the world’s first COVID-19 characterisation study which was proven to be safe and well tolerated
· Contract signed to manufacture a SARS-CoV-2 Delta variant challenge agent with Imperial College London, as part of a Wellcome Trust-funded initiative
· Opened a new quarantine clinic on a capital efficient basis to facilitate the growing demand for human challenge studies. This new facility, The Whitechapel Clinic, added 19 quarantine bedrooms for future challenge studies
· FluCamp screened c. 84,000 volunteers for human challenge studies in 2021 (2020: c.68,000); supported by the cost-efficient expansion of volunteer recruitment centre
o New London FluCamp volunteer recruitment centre – converted former coffee shop adjacent to the existing QMB facility
o New Manchester FluCamp volunteer recruitment centre
· Significant CRO experience added to the Board with the appointment of Yamin ‘Mo’ Khan as Non-Executive Director, who was appointed CEO post period end
· In June 2021, completed a distribution in specie to the Company’s shareholders, through the demerger of certain non-core assets into Poolbeg Pharma
Post-period end highlights
· Commenced development of a new influenza challenge model for an existing top five global pharmaceutical client and signed a £14.7m contract for the characterisation and challenge trial to follow
· £7.3m influenza challenge trial and £5m RSV challenge trial contracts signed
· Launched a new Malaria human challenge model and was awarded by an existing Big Pharma client to act as a vaccination site for a Phase II field study
· Opened a new primary FluCamp volunteer recruitment facility in Whitechapel, increasing bed capacity by 44% from 43 beds to 62 beds, and opened a new Manchester volunteer recruitment centre at the same cost as the old facility, but with four times the floor space, doubling the Group’s volunteer screening capacity to 1,000 per week
o Facilities expansion enables the Group to broaden the scope of the business to offer additional clinical trial services outside of its traditional core challenge study offering
Current trading and outlook
As at 1 June 2022, Open Orphan had an order book of signed contracts worth £64.2m which is expected to be recognised across 2022, 2023 and 2024.
Open Orphan’s pipeline of new opportunities continues to grow with a number of further challenge study opportunities at advanced negotiations across influenza, asthma, RSV, malaria and COVID-19. This growth is driven by the increased success and awareness of human challenge trials, and the development of new challenge models. A significant portion of our pipeline includes returning Big Pharma customers, in addition to a wider group of new clients who have observed the benefits of human challenge trials.
Our Venn Life Sciences subsidiary continues to deliver specialist drug development consultancy services across non-clinical and clinical development, pharmacology, CMC and biometry services, acting as a trusted partner to an extensive range of clients.
These developments reaffirm the Board’s expectations of a profitable growing business with revenues in the region of £50m in 2022.The Group is now well positioned and well capitalised to deliver sustainable long-term profitability.
Yamin ‘Mo’ Khan, Chief Executive Officer of Open Orphan, said: “2021 was a milestone year for Open Orphan; the Group achieved record revenues, and recorded full year EBITDA-profitability for the first time – a significant turning point for the business.
“The Group won a record number of human challenge study contracts, serving four of the top 10 global biopharma companies and more than 60 clients in total. We were proud to make a significant contribution to the UK Government’s response to the pandemic by completing the world’s first COVID-19 characterisation study, which furthered our understanding of COVID-19 disease progression. Importantly, the Group accomplished this whilst investing in operational improvements, with volunteer screening and quarantine capacities expanded during the year.
“Post-period end, we have continued our momentum from 2021 into a strong start to trading and significant contract wins. We increased our bed count from 43 to 62, doubled our volunteer screening capacity, and also expanded the scope of our business to offer additional clinical trial services, where we have already signed our first contracts, establishing new revenue streams for the business. We also launched our new Malaria Human Challenge Model, which I believe has further consolidated our position as the leading provider of human challenge trials in infectious and respiratory disease. In my new role as CEO, I look forward to driving further growth across the business this year and converting this substantial progress into value for our shareholders.”
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com. By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.
1 Source: Citeline Trialtrove, Jan. 2022 and Pharma R&D Annual Review; IQVIA Institute, Global Trends in R&D – Overview Through 2021; Global Data; Evaluate Pharma; Edison Investment Research; Pitchbook
For further information please contact:
Open Orphan plc |
+353 (0) 1 644 0007 |
||
Yamin ‘Mo’ Khan, Chief Executive Officer |
|||
Liberum Capital (Nominated Adviser and Joint Broker) |
+44 (0) 20 3100 2000 |
||
Ben Cryer/ Edward Mansfield/ Phil Walker/ Will King |
|||
|
|||
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
Geoff Nash / James Thompson / Richard Chambers |
|||
|
|||
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
Anthony Farrell |
|||
|
|||
Walbrook PR (Financial PR & IR) Paul McManus / Sam Allen / Louis Ashe-Jepson |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com +44 (0)7980 541 893 / +44 (0) 7502 558 258 / +44 (0)7747 515393 |
||
Notes to Editors
Open Orphan plc
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.
The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases, including the recently established COVID-19 model, and is developing a number of new models, such as Malaria, to address the dramatic growth of the global infectious disease market. The Paris and Breda offices have over 25 years of experience providing drug development services such as biometry, data management, statistics CMC, PK and medical writing to third party clients as well as supporting the London-based challenge studies.
Open Orphan runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. The newly opened facilities have expanded the scope of the business to enable the offering of Phase I and Phase II vaccine field trials, PK studies, bridging studies, and patient trials as part of large international multi-centre studies.
Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company’s Disease in Motion® platform, this unique dataset includes clinical, immunological, virological, and digital (wearable) biomarkers.
Link here for full financial statements
Open Orphan #ORPH – Notice of results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces that it will release its full year results for the year ended 31 December 2021 on Tuesday 7 June 2022.
Investor Presentation
Yamin ‘Mo’ Khan, Chief Executive Officer, and Leo Toole, Chief Financial Officer, will be hosting a live online presentation relating to the final results via the Investor Meet Company platform at 6pm on Tuesday 7 June 2022. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here.
Investors who already follow Open Orphan on the Investor Meet Company platform will automatically be invited.
Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the “Ask a Question” function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation and a PDF of the slides used will be available on the Investor Meet Company platform and the Company’s website afterwards.
BATM Advanced Communications #BVC – Result of General Meeting
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that at the general meeting of the Group held today, the resolution was duly passed.
Details of the proxy voting results, which should be read alongside the Notice of General Meeting, are below:
Resolution |
Votes for |
Votes against |
Votes withheld |
Total proxy votes |
||
No. of votes |
% of votes cast* |
No. of votes |
% of votes cast* |
No. of votes |
||
1 |
276,069,541 |
97.26 |
7,751,047 |
2.73 |
23,401 |
283,843,989 |
(There were no discretionary votes cast)
* Excludes withheld votes
Enquiries:
BATM Advanced Communications |
|
Dr Zvi Marom, Chief Executive Officer |
+972 9866 2525 |
Moti Nagar, Chief Financial Officer |
|
Shore Capital |
|
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)
|
+44 20 7408 4050 |
Luther Pendragon |
|
Harry Chathli, Claire Norbury |
+44 20 7618 9100 |
#BVC BATM Advanced Communication – Full year Results
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces its preliminary results for the year ended 31 December 2021.
Financial Summary
$m |
2021 |
2020 |
Change |
Results from ongoing operations (adjusted)* |
|||
Revenue |
132.8 |
112.6 |
+1 8.0 % |
Gross profit |
50.2 |
41.0 |
+22.5% |
Gross margin |
37.8% |
36.4% |
+140bps |
Operating profit |
11. 3 |
2.6 |
+339.5% |
EBITDA |
15.7 |
6.6 |
+138.8% |
|
|
|
|
Reported results |
|||
Revenue |
140.0 |
183.6 |
(23.7%) |
Gross profit |
51.1 |
60.7 |
(15.9%) |
Gross margin |
36.5% |
33.1% |
+340bps |
Operating profit |
24. 4 |
14.2 |
+71.3% |
EBITDA |
29.6 |
19.7 |
+50.4% |
Cash from operations |
8.7 |
20.1 |
(56.8%) |
Basic earnings per share (cents) |
3.26¢ |
2.22¢ |
+46.8% |
Cash and financial assets |
67.8 |
53.4 |
+26.9% |
* Adjusted to present the results on an ongoing operations basis by excluding (1) the contribution to both years from NGSoft, a subsidiary that the Group sold in March 2021, (2) the contribution to 2020 from a significant contract for the supply of ventilators, which was exceptional in nature, and (3) the amortisation of intangible assets for both years. The term ‘ongoing operations’ in this announcement is used for comparative purposes only and is not used in the same context as in accounting standards. For further information see Note 3 – Other alternative measures.
Operational Summary
Bio-Medical Division (84% of total revenue from ongoing operations)
· Revenue from ongoing operations ( excluding the contribution to 2020 from an exceptional ventilator contract) increased by 17.7% to $112.0m (2020: $95.2m), reflecting growth in all units
· Diagnostics Unit – revenue +38%
o Significant sales growth driven by strong global demand for COVID-19 test kits (reagents) and diagnostic instruments and supported by increased sales of products in other disease areas
o Expanded COVID-19 diagnostics portfolio with launch of new solutions, including a test that uses self-collected saliva samples and the RAPiDgen® SARS-CoV-2 Ag test for at-home use
o PCR and iso-thermal method being developed by the Group for the rapid and comprehensive diagnosis of tuberculosis received the backing of the Stop TB Partnership, an international alliance
· Eco-Med Unit – revenue +37% (excl. contribution from exceptional ventilator contract)
o Returned to underlying growth with delivery resuming on contracts for the installation of the Group’s ISS-based pathogenic waste treatment solution
o Progress made in projects with Ceva Animal Health and a Taiwanese agri-food conglomerate
o Awarded a contract for its agri-waste treatment solution by a cattle facility in Botswana – the Group’s first contract for its agri-waste solution in Africa
· Distribution Unit – revenue +9%
o Increased revenue driven by the distribution of several molecular tests and of COVID-19 diagnostic reagents and equipment
Networking and Cyber Division (16% of total revenue from ongoing operations)
· Revenue from ongoing operations (which excludes the contribution from NGSoft to both years) increased by 19.5% to $20.7m (2020: $17.3m) , reflecting underlying growth in both the Networking and Cyber units
· Networking Unit – revenue +13% (excl. contribution from NGSoft)
o Launched Edgility, an ecosystem of networking products and services for edge computing based on the Group’s network function virtualisation (“NFV”) technology
§ Won two edge computing contracts expected to be worth an aggregate of $2.7m over a multi-year period, which commenced generating revenue post year end
§ Successful proof-of-concepts conducted with several potential customers and partners worldwide, which the Group expects will translate to orders in 2022
§ Established four new partnerships, including one post period, to boost Edgility sales and market presence through the offering of joint solutions
§ Expanded addressable market with enhancement of Edgility OS to enable use for public cloud environments
o Network Edge (Carrier Ethernet)
§ Resumption of normal business practices resulted in an increase in revenue during the year and a substantial increase in backlog, which is for delivery in 2022
§ Awarded a contract from a new tier 1 telecommunications operator customer in APAC, which contributed significantly to the unit’s growth
· Cyber Unit – revenue +111%
o Awarded over $18m in cyber security contracts from a long-standing government defence department customer
o Delivery of these orders commenced during the year and will continue in 2022 and 2023
o The contracts include a $10m multi-year contract for the delivery of an advanced network security solution containing elements of NFV protection
Commenting on the results, Dr Zvi Marom, Chief Executive Officer of BATM, said: “ We are delighted to be announcing another excellent set of results with growth from ongoing operations in all of our business units. We are particularly proud of the significant progress made in our Diagnostics unit, where our investment in recent years has really come to fruition, and of the substantial contracts awarded during the year in our cyber business. We were also excited to launch our Edgility platform for edge computing and virtual networking, which we believe will be a key driver of our future growth.
“Looking ahead, we entered the new year with sustained momentum across the business and we remain on track to deliver significant growth for full year 2022, in line with market expectations. We have established solid foundations in core technologies that are now at an inflexion point of becoming market disrupters. We will continue to cultivate growth and development across our business as well as pursue opportunities to accelerate the realisation of the value of the IP within our different units through strategic transactions. We have an exciting future ahead of us and we look forward to reporting on our progress and delivering value for our shareholders. “
Enquiries:
BATM Advanced Communications |
|
Dr Zvi Marom, Chief Executive Officer |
+972 9866 2525 |
Moti Nagar, Chief Financial Officer |
|
|
|
Shore Capital |
|
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory) |
+44 20 7408 4050 |
Henry Willcocks (Corporate Broking) |
|
|
|
Luther Pendragon |
|
Harry Chathli, Claire Norbury |
+44 20 7618 9100 |